![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Peregrine's Tarvacin Effective in Imaging Prostate Cancer
Peregrine's Tarvacin Effective in Imaging Prostate Cancer
Peregrine Pharmaceuticals has reported data showing the potential use of Tarvacin, its lead anti-phospholipid therapy agent, for imaging solid tumors.
Data showed that Tarvacin could be used to deliver a radioactive arsenic compound to prostate cancer blood vessels for tumor imaging. Peregrine expects to begin patient enrollment in a Tarvacin Phase I clinical trial for the treatment of cancer within the next 30 days.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct